Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LEU-011 (Primary)
  • Indications Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms AERIAL Trial
  • Sponsors Leucid Bio

    • Most Recent Events

    • 21 Dec 2023 Status changed from planning to recruiting.
    • 21 Sep 2023 According to Leucid Bio media release, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorisation (CTA) to commence this trial
    • 21 Sep 2023 According to Leucid Bio media release, Company is on track to dose first patient in this trial during the fourth quarter of 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top